EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of the novel markers of PPAR signalling affecting immune microenvironment and immunotherapy response of lung adenocarcinoma patients

Wei Zhang iD, Junhui Liu, Xin Ren, Zhengbin Zhang, Meilan Zhou, Yuehua Li, Jianjie Wang, Quan Li, Qi Zhu, Gang Wu

Journal of Cellular and Molecular Medicine · 2024

DOI: 10.1111/jcmm.17877 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Wei Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Tuberculosis ward No1, Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, Affiliated to Janghan University, Wuhan, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Tumor Microenvironment, Peroxisome Proliferator-Activated Receptors, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Scientific Research Project of Health Commission of Hubei Province, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peroxisome proliferator‐activated receptors (PPARs) are essential for cellular physiological processes. However, there is less research on the PPAR‐related genes in lung adenocarcinoma (LUAD). Open‐access data were get from the cancer genome atlas (TCGA) and gene expression omnibus (GEO) databases. All the analysis were conducted in the R software based on different R packages. In this study, we gauged the PPAR score employing a set of 72 PPAR‐associated genes and probed the biological impact of this score on lung adenocarcinoma (LUAD). Subsequently, we established a unique signature composed of eight PPAR‐related genes (ANGPTL4, ACSL3, ADIPOQ, FABP1, SLC27A1, ACOX2, PPARD and OLR1) to forecast the prognosis of LUAD. The signature's effectiveness in predicting survival was validated through the receiver operating characteristic curve in the TCGA‐LUAD cohort. As per the pathway enrichment analysis, several crucial oncogenic pathways and metabolic processes were enriched in high‐risk individuals. Further, we observed that these high‐risk patients exhibited heightened genomic instability. Additionally, compared to the low‐risk cohort, high‐risk patients demonstrated diminished immune components and function. Intriguingly, high‐risk patients exhibited a potential heightened sensitivity to immunotherapy and certain drugs, including Gefitinib, Afatinib, Erlotinib, IAP_5620, Sapitinib, LCL161, Lapatinib and AZD3759. The prognosis model based on eight PPAR‐related genes has satisfactory prognosis prediction efficiency. Meanwhile, our results can provide direction for future studies in the relevant aspects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungTumor MicroenvironmentPeroxisome Proliferator-Activated ReceptorsGene Expression Regulation, NeoplasticSignal TransductionLung NeoplasmsImmunotherapyBiomarkers, TumorHumansPrognosisGene Expression ProfilingMaleROC Curve

Stichwörter der Autor:innen

GEOPPARTCGAlung adenocarcinomaprognosis

Substanzen

Peroxisome Proliferator-Activated ReceptorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Tuberculosis ward No1, Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, Affiliated to Janghan University, Wuhan, China.
  • Department of Tuberculosis Control, Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control Affiliated to Janghan University, Wuhan, China.
  • Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, Wuhan, China.
  • Medical department, Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, Affiliated to Janghan University, Wuhan, China.

ORCID-Profile: Wei Zhang

Förderung

  • Health Scientific Research Project of Health Commission of Hubei Province, China

Zitieren

APA

Zhang, W., Liu, J., Ren, X., Zhang, Z., Zhou, M., Li, Y., Wang, J., Li, Q., Zhu, Q., & Wu, G. (2024). Identification of the novel markers of PPAR signalling affecting immune microenvironment and immunotherapy response of lung adenocarcinoma patients. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.17877

Vancouver

Zhang W, Liu J, Ren X, Zhang Z, Zhou M, Li Y, et al. Identification of the novel markers of PPAR signalling affecting immune microenvironment and immunotherapy response of lung adenocarcinoma patients. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.17877

BibTeX
@article{Zhang2024,
  author = {Zhang, Wei and Liu, Junhui and Ren, Xin and Zhang, Zhengbin and Zhou, Meilan and Li, Yuehua and Wang, Jianjie and Li, Quan and Zhu, Qi and Wu, Gang},
  title = {Identification of the novel markers of PPAR signalling affecting immune microenvironment and immunotherapy response of lung adenocarcinoma patients},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  doi = {10.1111/jcmm.17877}
}
Kostenlos starten →